The combination therapy with the cytotoxic T lymphocyte-associated antigen-4 and programmed death 1 antibody-induced asthma in a patient with advanced melanoma.
J Cancer Res Ther
; 17(3): 808-810, 2021 Jul.
Article
en En
| MEDLINE
| ID: mdl-34269318
ABSTRACT
The combination of programmed death 1 (PD-1) inhibitors and cytotoxic T lymphocyte-associated antigen-(CTLA-4) inhibitors have markedly improved the survival of melanoma patients. We report the case of a patient with advanced melanoma who developed asthma during anti-PD-1 and anti-CTLA-4 combination therapy. The patient was a 57-year-old woman enrolled in a clinical trial regarding novel CTLA-4 antibody and sintilimab treatment. The patient was diagnosed with asthma after three cycles of therapy. Subsequently, she was treated with corticosteroids, shortcostero ß2 agonists, and antihistamines. The symptoms were relieved after 7 days. This is the first report of asthma in a patient treated with combination immunotherapy to the best of our knowledge. The mechanism remains to be further explored.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Asma
/
Neoplasias Cutáneas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Inhibidores de Puntos de Control Inmunológico
/
Melanoma
Tipo de estudio:
Clinical_trials
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2021
Tipo del documento:
Article